Supreme Court to Decide Fate of Major Lawsuits Alleging Cancer Link to Roundup Weedkiller

The Supreme Court is weighing a high-stakes dispute over whether the popular weedkiller Roundup must carry a cancer warning label, a decision that could reshape thousands of lawsuits already filed across the country. At the center is a single California man’s case, but the ruling will determine how far companies like Bayer can rely on federal regulators to shield them from state-law failure-to-warn claims.

The outcome will reverberate far beyond one product, affecting farmers, homeowners, regulators and investors. It will also signal how aggressively the Court expects companies to warn about alleged health risks when scientific and regulatory bodies are divided.

What happened

The case before the Court stems from a lawsuit filed by a California resident who used Roundup for years and later developed non-Hodgkin lymphoma. He argued that Monsanto, which created Roundup and is now owned by Bayer, failed to warn that glyphosate, the herbicide’s active ingredient, could cause cancer. A jury agreed and awarded damages, and California courts upheld the verdict under the state’s failure-to-warn law.

Bayer asked the Supreme Court to step in, arguing that federal pesticide law preempts, or overrides, state requirements for additional cancer warnings on Roundup’s label. The company points to the Environmental Protection Agency’s repeated approvals of glyphosate products and the agency’s conclusion that glyphosate is “not likely” to be carcinogenic at real-world exposure levels. Bayer contends that California cannot force a label that, in its view, conflicts with that federal determination, and it has framed the dispute as a test of whether federal regulators or state juries set national warning standards.

During arguments, several justices pressed lawyers on whether the Federal Insecticide, Fungicide, and Rodenticide Act leaves room for states to impose extra warnings when new evidence emerges, or whether EPA’s label is the final word. The case also folds in California’s Proposition 65, which requires warnings for chemicals “known to the state” to cause cancer. California added glyphosate to that list after the International Agency for Research on Cancer classified it as “probably carcinogenic,” a move that helped fuel litigation and state-level warning efforts.

For plaintiffs, the lawsuit is part of a broader wave of Roundup claims that have already cost Bayer billions of dollars in verdicts and settlements. For Bayer, it is a carefully chosen vehicle to secure a national precedent that could shut down many remaining cases. The company has said that a favorable ruling would significantly limit its future liability and clarify its obligations to follow federal labels rather than a patchwork of state rules.

The case has drawn intense attention from business groups, farm organizations and public-health advocates. Industry allies argue that allowing each state to demand its own warnings would undermine uniform national pesticide regulation and overwhelm companies with conflicting requirements. Consumer and environmental groups counter that state tort suits are a vital backstop when federal regulators move slowly or rely on contested science, and they stress that juries have repeatedly credited evidence linking long-term Roundup use to non-Hodgkin lymphoma.

Why it matters

The immediate stakes involve thousands of existing and potential Roundup lawsuits. Bayer has faced a torrent of claims from landscapers, groundskeepers and home gardeners who say years of exposure to glyphosate caused their cancer. The company has already agreed to pay large settlement sums and has lost several high-profile jury trials, with some verdicts reaching into the tens or hundreds of millions of dollars before being reduced on appeal. A Supreme Court ruling that federal law preempts state failure-to-warn suits could sharply curtail that litigation and save Bayer from future payouts that analysts estimate in the billions.

The decision will also define how much legal weight federal agency judgments carry when individuals seek remedies under state law. If the Court holds that EPA’s glyphosate assessments block state warning claims, companies across the chemical and pharmaceutical industries will have a stronger shield whenever they can point to federal approvals. That outcome would delight corporate defendants and many national trade groups but would narrow one of the main tools that injured consumers use to challenge product safety.

On the other side, if the Court allows the California verdict to stand, it will affirm that federal pesticide registration is a floor, not a ceiling, for safety obligations. That would energize plaintiffs’ lawyers and could spur more state-level suits over other widely used chemicals. It would also put pressure on companies to add warnings that go beyond what EPA or other federal regulators explicitly require, in order to avoid the risk of large jury awards.

The case highlights a deeper scientific and regulatory split over glyphosate. While EPA and several other regulators have said that glyphosate is unlikely to cause cancer at typical exposure levels, the International Agency for Research on Cancer reached a very different conclusion. California’s decision to list glyphosate under Proposition 65 relied heavily on that international finding, which in turn has been central to many plaintiffs’ arguments. The Supreme Court is not being asked to decide who is scientifically correct, but its ruling will determine which judgments matter most when companies decide what to tell users.

Beyond the courtroom, the ruling will shape what consumers see on store shelves. If Bayer loses, Roundup sold in California could carry a cancer warning that is absent in other states, unless the company chooses to adopt a uniform national label. That prospect has already drawn concern from farm groups that rely on Roundup for crops such as corn and soybeans and from small businesses that provide landscaping services. They argue that inconsistent labels could confuse users and stigmatize a product that federal regulators continue to approve.

Politically, the case has become a flashpoint in debates over regulation and corporate accountability. Supporters of stricter warnings portray the litigation as a test of whether large chemical companies can be held responsible for long-term health risks. Business-aligned politicians and advocacy groups see it as a referendum on the power of state juries to second-guess federal agencies. The fact that Roundup is used by homeowners in products sold at retailers such as Home Depot and Lowe’s, as well as by large-scale farmers, gives the case a reach that extends into suburban backyards and industrial agriculture alike.

What to watch next

The Court’s decision will turn on how a majority interprets the interaction between federal pesticide law and state failure-to-warn claims. Observers are watching for whether the justices adopt a broad preemption rule that could affect many regulated products or craft a narrower holding limited to glyphosate and EPA’s specific findings. The justices’ questions during argument suggested concern about both undermining federal uniformity and stripping states of their traditional role in protecting consumers through tort law.

If the Court sides with Bayer, thousands of pending Roundup cases that rely on state warning theories could be dismissed or sharply limited, and future plaintiffs would face a higher bar. Plaintiffs’ lawyers might try to pivot to alternative theories, such as design defect or negligent misrepresentation, but those claims can be harder to prove. A victory for Bayer could also embolden other companies to challenge state-law suits whenever they can point to federal approvals, especially in areas like pharmaceuticals, medical devices and other pesticides.

If the Court rules for the California plaintiff, Bayer will likely have to continue managing a large docket of Roundup litigation and could face pressure to reach broader settlements. The company has already explored reformulating some consumer products and has discussed potential changes to labeling, but a loss would increase the urgency of those steps. Other chemical manufacturers would study the opinion closely to gauge how much additional warning language is needed to reduce exposure to state-law claims.

Regulators will also be watching. EPA may feel pressure to revisit or clarify its glyphosate assessments, particularly if the Court emphasizes scientific disputes that have unfolded in the record. State regulators, especially in jurisdictions with their own right-to-know or warning statutes, could see a green light to push for stronger labels or additional restrictions on products that raise cancer concerns.